By writing a custom computer algorithm that mapped every possible version of a rare class of geometric shapes, 17-year-old ...
Vertex Pharmaceuticals (NASDAQ:VRTX) stock drew attention as gene therapy sales climbed and an expanded approval broadened ...
Vertex Pharmaceuticals is executing a pivotal transition year, evolving from a CF-dominated biotech to a multi-franchise ...
(NASDAQ: VERX) (“Vertex” or the “Company”) , the Decision-to-Defense™ global indirect tax and compliance company, today released new research pointing to a structural shift in how global enterprises ...
Good morning, and welcome to the Vertex First (sic) [ Second ] Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. If you have any objections, please ...
StockStory.org on MSN
Vertex Pharmaceuticals (NASDAQ:VRTX) beats Q2 CY2026 sales expectations, full-year outlook slightly exceeds expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) announced in Q2 CY2026, with sales up 12.5% year on year to $3.33 ...
Build VFX with optimisation in mind from the outset to avoid performance issues later in production. VFX budgets should be ...
Despite the bottleneck caused by the lack of foundries, investors are still backing AI chip startups. Pang, for one, has ...
A growing number of law firms are embracing partnerships with Big Tech and legal tech companies, with one recent example ...
NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma’s economics ...
SLA-backed regional inference, five-year European Compute Unit contracts, hosting China's GLM-5.2, and 1 gigawatt of compute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results